The IMS Core will continue to coordinate efficient and consistent utilization of neuroimaging and nonneuroimaging measures and provide statistical support across projects and cores for this program project grant (PPG). The IMS Core provides methods and staff support that is readily accessible to investigators and is a technical core for image data acquisition, processing, analysis, and evaluation. The Core also provides data management support and is an integral component of each project and is linked to all projects and Cores. The IMS core will also continue to: 1) provide valid and standardized neuroimaging methods for PET and MR data acquisition with timely analysis and evaluation;2) provide data management that ensures timely and secure data entry, storage, retrieval, quality control (QC) checks, and archiving;3) provide statistical consultation;and 4) serve as a methodology training resource. The IMS Core aims for the PPG renewal period are:
Aim 1. To acquire and manage neuroimaging data used to assess amyloid deposition and metabolic rate (via PET) and tissue volume, morphometric differences, white matter lesions, and blood flow (via MRI) Aim 2. To provide robust structural and functional neuroimaging measures for primary (and exploratory) aims Aim 3. To provide tools that can be used to determine temporal and spatial characteristics of neuroimaging measures across time and relative to non-imaging covariates and/or post-mortem correlates Aim 4. To provide imaging and statistical consultation to investigators to achieve the project aims Aim 5. To provide training to students and faculty in amyloid imaging and related neuroimaging methodology.
;The IMS Core activities have helped to build a strong PiB PET research infrastructure that allows for efficient pooling of resources and experience that is needed to further PPG research goals and support further development, refinement, and validation of tools for collaborative research efforts.
|Perez, Sylvia E; He, Bin; Nadeem, Muhammad et al. (2015) Resilience of precuneus neurotrophic signaling pathways despite amyloid pathology in prodromal Alzheimer's disease. Biol Psychiatry 77:693-703|
|Klunk, William E; Koeppe, Robert A; Price, Julie C et al. (2015) The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET. Alzheimers Dement 11:1-15.e1-4|
|Pivtoraiko, Violetta N; Abrahamson, Eric E; Leurgans, Sue E et al. (2015) Cortical pyroglutamate amyloid-? levels and cognitive decline in Alzheimer's disease. Neurobiol Aging 36:9-Dec|
|McDade, Eric; Kim, Albert; James, Jeffrey et al. (2014) Cerebral perfusion alterations and cerebral amyloid in autosomal dominant Alzheimer disease. Neurology 83:710-7|
|Cohen, Ann D; Klunk, William E (2014) Early detection of Alzheimer's disease using PiB and FDG PET. Neurobiol Dis 72 Pt A:117-22|
|Hong, Young T; Veenith, Tonny; Dewar, Deborah et al. (2014) Amyloid imaging with carbon 11-labeled Pittsburgh compound B for traumatic brain injury. JAMA Neurol 71:23-31|
|Lopez, Oscar L; Klunk, William E; Mathis, Chester et al. (2014) Amyloid, neurodegeneration, and small vessel disease as predictors of dementia in the oldest-old. Neurology 83:1804-11|
|Hughes, Timothy M; Kuller, Lewis H; Barinas-Mitchell, Emma J M et al. (2014) Arterial stiffness and ?-amyloid progression in nondemented elderly adults. JAMA Neurol 71:562-8|
|Gandy, Sam; Ikonomovic, Milos D; Mitsis, Effie et al. (2014) Chronic traumatic encephalopathy: clinical-biomarker correlations and current concepts in pathogenesis. Mol Neurodegener 9:37|
|Mizukami, Katsuyoshi; Abrahamson, Eric E; Mi, Zhiping et al. (2014) Immunohistochemical analysis of ubiquilin-1 in the human hippocampus: association with neurofibrillary tangle pathology. Neuropathology 34:11-8|
Showing the most recent 10 out of 59 publications